Oseltamivir is manufactured by Roche and is used to treat avian flu. ## Compulsory licenses Compulsory licenses have been issued for Oseltamivir in the following instance: ### Argentina issued on October 01, 2005 [[Argentina 1]]'s provisions on compulsory licences can be in the Patent Law (Law No. 24.481), consolidated by Decree 260/1996. There are several grounds for issuing a compulsory licence. - Lack of Exploitation / Non-working Patent not used within 3 years post-grant (or 4 years post-filing), or uninterrupted interruption exceeding 1 year—except due to force majeure. - Failure to Negotiate Voluntary License After 150 days of seeking a reasonable license and failing, a compulsory license can be requested. - Anti‑competitive or Unfair Practices Abusive conduct, excessive or discriminatory pricing, refusal to supply the local market, or interference in competition may trigger licensing. - National Emergency or Public Health / Security Government may authorize use “without authorization of the holder” for emergencies affecting health or national security. - Dependent Patents If exploiting a second patent requires infringing an earlier one, a compulsory cross-license may be granted. - Public/Non-commercial Government Use Use for non-commercial public purposes must notify the patent holder and is subject to fair remuneration. - High Prices or Supply Issues in Health Sector Under the 2019 Social Solidarity Law, the Ministry of Health can invoke compulsory licensing to address unreasonable price hikes or shortages impacting public access to medicines. More information can be found [here](https://www.argentina.gob.ar/normativa/nacional/ley-24481-27289). However, a compulsory license has not been executed for Oseltamivir in this case because: no patent. ## Other products issued by the same manufacturer [[Erlotinib]] [[Oseltamivir]] [[NFV]] [[T-20]] [[Trastuzumab-Emtansine]] [[Pertuzumab]] ## Other products for the same disease